BioAge Labs (NASDAQ:BIOA) Reaches New 1-Year High – Here’s Why

Shares of BioAge Labs, Inc. (NASDAQ:BIOA) hit a new 52-week high during mid-day trading on Thursday . The company traded as high as $24.42 and last traded at $24.5980, with a volume of 180857 shares traded. The stock had previously closed at $22.83.

Wall Street Analyst Weigh In

Several research firms have commented on BIOA. Needham & Company LLC assumed coverage on shares of BioAge Labs in a research report on Friday, March 27th. They set a “buy” rating and a $50.00 target price on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of BioAge Labs in a report on Friday, April 24th. Wall Street Zen downgraded BioAge Labs from a “hold” rating to a “sell” rating in a research report on Sunday, May 17th. Roth Mkm initiated coverage on BioAge Labs in a report on Wednesday, May 27th. They set a “buy” rating and a $36.00 price target on the stock. Finally, BTIG Research assumed coverage on BioAge Labs in a research report on Wednesday, May 13th. They issued a “buy” rating and a $40.00 price objective on the stock. Six analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $43.50.

BioAge Labs Stock Up 5.0%

The firm has a market cap of $1.06 billion, a P/E ratio of -9.90 and a beta of 0.94. The firm’s 50-day simple moving average is $18.05 and its 200 day simple moving average is $17.87.

BioAge Labs (NASDAQ:BIOA) last released its earnings results on Friday, May 8th. The company reported ($0.52) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.71) by $0.19. The firm had revenue of $2.77 million during the quarter. BioAge Labs had a negative net margin of 871.75% and a negative return on equity of 29.40%. As a group, analysts forecast that BioAge Labs, Inc. will post -2.68 earnings per share for the current year.

Institutional Trading of BioAge Labs

A number of large investors have recently bought and sold shares of the company. Janus Henderson Group PLC lifted its position in shares of BioAge Labs by 411.8% during the 1st quarter. Janus Henderson Group PLC now owns 2,094,270 shares of the company’s stock valued at $36,597,000 after buying an additional 1,685,063 shares during the last quarter. Adage Capital Partners GP L.L.C. bought a new position in shares of BioAge Labs during the 4th quarter worth $13,892,000. Stempoint Capital LP purchased a new stake in BioAge Labs in the 1st quarter worth about $5,923,000. Millennium Management LLC increased its holdings in BioAge Labs by 749.8% in the 3rd quarter. Millennium Management LLC now owns 306,552 shares of the company’s stock worth $1,803,000 after acquiring an additional 270,479 shares during the last quarter. Finally, Sphera Funds Management LTD. bought a new stake in BioAge Labs in the 4th quarter valued at about $3,215,000.

About BioAge Labs

BioAge Labs (NASDAQ: BIOA) is a clinical-stage biotechnology company focused on discovering and developing therapies that address age-associated diseases. The company leverages its proprietary analytics platform to mine large-scale human biological data for insights into the molecular mechanisms of aging. By targeting fundamental aging pathways, BioAge aims to create interventions that extend healthspan and treat conditions that disproportionately affect older populations.

At the core of BioAge’s operations is its integrated drug discovery platform, which combines human omics datasets, machine learning algorithms and experimental validation to identify novel drug targets.